Navigation Links
BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/8/2009

nd other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current phar
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 5, 2015  23andMe, Inc., the leading personal genetics ... Research Study in collaboration with Pfizer Inc. The ... erythematosus, more commonly known as lupus, into the study ... effort is also in collaboration with the Lupus Research ... May. Approximately 1.5 million people in the ...
(Date:5/5/2015)... , May 5, 2015 Psyche Systems Corporation ... which offers a first-of-its-kind platform that helps labs comply ... lab results, transforms the way patients engage with these ... Luminate Health provides a HIPAA-compliant digital platform that ... manage, and understand their lab results, and uniquely connects ...
(Date:5/5/2015)... May 5, 2015 Reprints Desk, Inc., a ... on-demand access to scientific, technical and medical (STM) content, ... Association of Southeastern Research Libraries (ASERL) . ... located across 11 southeastern states. Founded in 1956, ASERL ... programs to address the continually changing needs of its ...
(Date:5/5/2015)... 2015 Franz Inc ., the leading ... that its flagship product, AllegroGraph, has been named a Champion ... Update report. AllegroGraph is a high performance Semantic ... standards. Graph databases are skyrocketing in popularity and have grown ... recent DBMS ranking by DB-Engines. , “We are ...
Breaking Biology Technology:23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... Pharmaceuticals, Inc. (NYSE Amex: AEN ), a ... for serious illnesses, announced today that it received approval at ... name to Synthetic Biologics, Inc. It is expected that ... name and stock ticker symbol, "SYN", effective as of ...
... of British Columbia professor has developed a new class of ... loss of consciousness in rats, and which are now ... "petit mal seizures," are a symptom of epilepsy, most commonly ... but dazed. The seizures, arising from a flurry of high-frequency ...
... 2012  ERT (NASDAQ: ERT ), a global ... devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), ... to further elevate its market and thought leadership position. ... months, web traffic to ERT,s website increased by 41% ...
Cached Biology Technology:New drugs show promise for preventing 'absence seizures' in children: UBC research 2ERT Launches New Website to Support Significant Commercial Growth 2
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... Olympus America Inc. formally introduced its advanced technology ... invasive single-site surgery through the umbilicus (belly button), ... post-operative pain, less internal/external scarring and improved recovery ... Society of American Gastrointestinal and Endoscopic Surgeons meeting, ...
... the phenomenon called "red tide" is expected to be ... at the Woods Hole Oceanographic Institution (WHOI) and North ... in part on a regional seafloor survey of quantities ... toxin that accumulates in clams, mussels and other shellfish ...
... BOSTON Eating salmon or other fatty fish just once ... to growing evidence that omega-3 fatty acids are of benefit ... Deaconess Medical Center (BIDMC) and reported in today,s on-line issue ... one of the largest studies to investigate the association. ...
Cached Biology News:Olympus advances technology for laparo-endoscopic single-site surgery 2Marine scientists warn of potential for spring, summer red tide outbreak in Gulf of Maine 2Marine scientists warn of potential for spring, summer red tide outbreak in Gulf of Maine 3Eating fatty fish once a week reduces men's risk of heart failure 2Eating fatty fish once a week reduces men's risk of heart failure 3
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
... for in vitro diagnostic assays, all EIA/RIA ... for uniform binding, high optical clarity and ... are part of the Certified Surface Chemistry ... be within QA release specifications. Linkage: This ...
... aqueous solution that contains a purified bovine ... a saline solution, pH 6.5 7.5, ... and 0.02% bromonitrodioxane as a preservative. ... stabilizer for biologically active components in solution, ...
AC input: 230 V...
Biology Products: